Search results for "outcomes"

showing 10 items of 446 documents

Fifteen operationally important decisions in the planning of biodiversity offsets

2018

Many development projects, whether they are about construction of factories, mines, roads, railways, new suburbs, shopping malls, or even individual houses, have negative environmental consequences. Biodiversity offsetting is about compensating that damage, typically via habitat restoration, land management, or by establishment of new protected areas. Offsets are the fourth step of the so-called mitigation hierarchy, in which ecological damage is first avoided, minimized second, and third restored locally. Whatever residual damage remains is then offset. Offsetting has been increasingly adopted all around the world, but simultaneously serious concerns are expressed about the validity of the…

0106 biological sciencesBiodiversity offsettingComputer scienceta1172FrameworkCONSERVATIONLand managementBiodiversity010501 environmental sciencesResidualECOLOGY010603 evolutionary biology01 natural sciences12. Responsible consumptionOperational designAdditionalityMANAGEMENTympäristövastuuOffset ratioRestoration ecologyEcology Evolution Behavior and SystematicsMultiplier1172 Environmental sciences0105 earth and related environmental sciencesNature and Landscape ConservationRESTORATIONOUTCOMESSubjective judgmentPERMANENCEEcological compensation15. Life on landEnvironmental economicsPOLICYkompensointibiodiversiteettiCONTEXTympäristövaikutukset13. Climate actionNo net lossADDITIONALITYta1181Time preferenceFlexibility
researchProduct

Three ways to deliver a net positive impact with biodiversity offsets

2020

Biodiversity offsetting is the practice of using conservation actions, such as habitat restoration, management, or protection, to compensate for ecological losses caused by development activity, including construction projects. The typical goal of offsetting is no net loss (NNL), which means that all ecological losses are compensated for by commensurate offset gains. We focused on a conceptual and methodological exploration of net positive impact (NPI), an ambitious goal that implies commitment beyond NNL and that has recently received increasing attention from big business and environmental nongovernmental organizations. We identified 3 main ways NPI could be delivered: use of an additiona…

0106 biological sciencesbiodiversity offsettingConservation of Natural Resourcesekologinen kompensaatioBiodiversity offsettingComputer scienceganancia netanet gainpermanenciaimpacto negativo netojerarquia alterna de mitigacioncompensacion ecologica010603 evolutionary biology01 natural sciencesCorollarycompensacion por biodiversidadmitigation hierarchynet negative impactEvaluation periodpermanencealternate mitigation hierarchyecological compensationEcosystemEcology Evolution Behavior and Systematics1172 Environmental sciencesNature and Landscape ConservationMotivationOUTCOMESEcology010604 marine biology & hydrobiologylieventäminenCommerceBiodiversity15. Life on landEnvironmental economicsluonnon monimuotoisuusbiodiversiteettipysyvyys13. Climate actionNet gain1181 Ecology evolutionary biology
researchProduct

Breastfeeding Practices Influence the Breast Milk Microbiota Depending on Pre-Gestational Maternal BMI and Weight Gain over Pregnancy

2021

Breastfeeding is critical for adequate neonatal microbial and immune system development affecting neonate health outcomes in the short and long term. There is a great interest in ascertaining which are the maternal factors contributing to the milk microbiota and the potential relevance for the developing infant. Thus, our study aimed to characterize the effect of mixed and exclusive breastfeeding practices on the milk microbiota and to determine the impact of pre-pregnancy body mass index (BMI) and weight gain over pregnancy on its composition. Breast milk samples from 136 healthy women were collected within the first month post-partum and milk microbiota profiling was analyzed by 16S rRNA …

0301 basic medicineAdultbreastfeeding030106 microbiologyBreastfeedingBreastfeedingbody mass indexBreast milkHealth outcomesArticle03 medical and health sciencesfluids and secretionsEnvironmental healthmedicineHumansTX341-641Body mass indexBifidobacterium2. Zero hungerPregnancyNutrition and DieteticsbiologyBacteriaMilk Humanbusiness.industryNutrition. Foods and food supplyMicrobiotabiology.organism_classificationmedicine.diseaseGestational Weight Gain3. Good health030104 developmental biologyBreast FeedingGestationFemalemedicine.symptombusinessBody mass indexWeight gainFood ScienceNutrients
researchProduct

Renin-Angiotensin System Inhibition in Cardiovascular Patients at the Time of COVID19: Much Ado for Nothing? A Statement of Activity from the Directo…

2020

Cardiovascular diseases, in particular hypertension, as well as the cardiovascular treatment with Renin-Angiotensin System inhibitors such as Angiotensin Converting Enzyme (ACE) inhibitors and Angiotensin Receptor Blockers (ARBs), are claimed once again as mechanisms of Severe Acute Respiratory Syndrome (SARS) during the COVID-19 outbreak due to Cov-2 epidemics. In vitro studies are available to support the eventual role of ACE inhibitors and ARBs in both the promotion and antagonism of the disease. The available literature, indeed, presents contrasting results, all concentrated in experimental models. Evidence in humans is lacking that those mechanisms are actually occurring in the present…

0301 basic medicineAngiotensin-Converting Enzyme InhibitorsDiseaseoutcomescardiovascular diseases; COVID-19; hypertension; infection; outcomes; Betacoronavirus; COVID-19; Cardiovascular Diseases; Humans; Hypertension; Italy; SARS-CoV-2; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Coronavirus Infections; Pandemics; Pneumonia Viral; Renin-Angiotensin SystemRenin-Angiotensin System0302 clinical medicinecardiovascular diseaseViralAngiotensin Receptor AntagonistsbiologyAngiotensin Receptor AntagonistAntihypertensive AgentItalyoutcomeAngiotensin Receptor BlockersCoronavirus InfectionsCardiology and Cardiovascular MedicineHumanmedicine.medical_specialtyhypertensionCoronavirus disease 2019 (COVID-19)Pneumonia ViralBetacoronavirusAngiotensin Receptor Antagonists03 medical and health sciencesPharmacotherapyRenin–angiotensin systemInternal MedicinemedicineHumansIntensive care medicinePandemicsAntihypertensive Agentsoutcomes.BetacoronaviruPandemicCoronavirus InfectionSARS-CoV-2business.industryOutbreakCOVID-19Angiotensin-Converting Enzyme InhibitorAngiotensin-converting enzymePneumoniacardiovascular diseases; COVID-19; hypertension; infection; outcomesinfectioncardiovascular diseases030104 developmental biologybiology.proteincardiovascular diseases; COVID-19; hypertension; infection; outcomes; betacoronavirus; cardiovascular diseases; humans; hypertension; Italy; angiotensin receptor antagonists; angiotensin-converting enzyme inhibitors; antihypertensive agents; coronavirus infections; pandemics; pneumonia viral; renin-angiotensin systembusiness030217 neurology & neurosurgery
researchProduct

Apolipoprotein B is regulated by gonadotropins and constitutes a predictive biomarker of IVF outcomes

2016

Background Follicular fluid (FF) is an important micro-environment influencing oocyte growth, its development competence, and embryo viability. The FF content analysis allows to identify new relevant biomarkers, which could be predictive of in vitro fertilization (IVF) outcomes. Inside ovarian follicle, the amount of FF components from granulosa cells (GC) secretion, could be regulated by gonadotropins, which play a major role in follicle development. Methods This prospective study included 61 female undergoing IVF or Intra-cytoplasmic sperm injection (ICSI) procedure. Apolipoprotein B (APOB) concentrations in follicular fluid and APOB gene and protein expression in granulosa cells from rep…

0301 basic medicineApolipoprotein Bmedicine.medical_treatment[SDV]Life Sciences [q-bio]Human follicular fluidOocyte RetrievalChorionic GonadotropinHuman chorionic gonadotropinFollicle-stimulating hormone0302 clinical medicineEndocrinologyProspective Studies030219 obstetrics & reproductive medicinebiologyObstetrics and Gynecology[SDV] Life Sciences [q-bio]Treatment Outcomemedicine.anatomical_structureFemalelipids (amino acids peptides and proteins)Apolipoprotein BEmbryo qualityAdultmedicine.medical_specialtyendocrine systemEmbryonic DevelopmentFertilization in Vitro03 medical and health sciencesOvulation InductionInternal medicinemedicineIVF outcomesHumansOvarian follicleApolipoproteins BHuman granulosa cellsGranulosa CellsIn vitro fertilisation[ SDV ] Life Sciences [q-bio]ResearchEmbryo MammalianOocyteFollicular fluidFollicular Fluid030104 developmental biologyEndocrinologyReproductive MedicineFertilizationbiology.proteinFollicle Stimulating HormoneBiomarkersGonadotropinsDevelopmental BiologyReproductive Biology and Endocrinology
researchProduct

DEBATE: Do interventions based on behavioral theory work in the real world?

2019

Abstract Background Behavioral scientists suggest that for behavior change interventions to work effectively, and deliver population-level health outcomes, they must be underpinned by behavioral theory. However, despite implementation of such interventions, population levels of both health outcomes and linked behaviors have remained relatively static. We debate the extent to which interventions based on behavioral theory work in the real world to address population health outcomes. Discussion Hagger argues there is substantive evidence supporting the efficacy and effectiveness of interventions based on behavioral theory in promoting population-level health behavior change in the ‘real world…

0301 basic medicineComparative Effectiveness ResearchEfficacyDebateApplied psychologyPopulationHealth BehaviorPsychological interventionMedicine (miscellaneous)Behavioural sciencesPhysical Therapy Sports Therapy and RehabilitationEffectivenessPopulation healthHealth behaviour changeMedical and Health SciencesEducation03 medical and health sciences0302 clinical medicineBehavior TherapyBehavioral and Social ScienceHumans030212 general & internal medicineCausationeducationlcsh:RC620-627education.field_of_studyBehavior030109 nutrition & dieteticsNutrition and DieteticsPopulation HealthBehavioural interventionsPreventionlcsh:Public aspects of medicineBehavior changelcsh:RA1-1270Health outcomeslcsh:Nutritional diseases. Deficiency diseasesParadigm shiftImplementationSpiteGeneric health relevancePublic HealthPsychologyInternational Journal of Behavioral Nutrition and Physical Activity
researchProduct

Uterine microbiome—low biomass and high expectations†

2018

AbstractThe existence of different bacterial communities throughout the female reproductive tract has challenged the traditional view of human fetal development as a sterile event. There is still no consensus on what physiological microbiota exists in the upper reproductive tract of the vast majority of women who are not in periods of infection or pregnancy, and the role of bacteria that colonize the upper reproductive tract in uterine diseases or pregnancy outcomes is not well established. Despite published studies and advances in uterine microbiome sequencing, some study aspects—such as study design, sampling method, DNA extraction, sequencing methods, downstream analysis, and assignment …

0301 basic medicineGenital Neoplasms Femalemedicine.medical_treatmentReproductive tractUterusPhysiologyBiology03 medical and health sciences0302 clinical medicinePregnancymedicineHumansBiomassPrecision MedicineUterine microbiomePregnancy outcomesPregnancy030219 obstetrics & reproductive medicineAssisted reproductive technologyMicrobiotaUterusFemale infertilityGenitalia FemaleCell BiologyGeneral Medicinemedicine.diseasePregnancy Complications030104 developmental biologymedicine.anatomical_structureReproductive MedicineHuman fetalFemaleGenital Diseases FemaleBiology of Reproduction
researchProduct

A multidimensional approach to frailty in older people

2020

Frailty is an important factor determining a higher risk of adverse health outcomes in older adults. Although scientific community in the last two decades put a lot of effort for its definition, to date no consensus was reached on its assessment. The mainstream thinking describes frailty as a loss of physical functions or as accumulation of multiple deficits. Recently, a novel conceptual model of frailty has emerged based on the loss of harmonic interaction between multiple domains (also referred as dimensions) including genetic, biological, functional, cognitive, psychological and socio-economic domain that ultimately lead to homeostatic instability. Therefore, the multidimensional aspects…

0301 basic medicineGerontologyAgingInstitutionalisationFrail Elderlymedia_common.quotation_subjectFrail Older AdultsPopulationComprehensive geriatric assessmentHealth outcomesBiochemistryArticle03 medical and health sciences0302 clinical medicineMultidimensional prognostic indexHumanseducationGeriatric AssessmentMolecular BiologyAgedmedia_commonAged 80 and overeducation.field_of_studyFrailtyGeriatric assessmentCognitionPrognosis030104 developmental biologyNeurologyConceptual modelPsychologyOlder people030217 neurology & neurosurgeryBiotechnologyAgeing Research Reviews
researchProduct

Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-alpha and -delta, Induces Resolution of Nonalcoholic Steatohepatitis Withou…

2016

International audience; BACKGROUND & AIMS: Elafibranor is an agonist of the peroxisome proliferator-activated receptor-α and peroxisome proliferator-activated receptor-δ. Elafibranor improves insulin sensitivity, glucose homeostasis, and lipid metabolism and reduces inflammation. We assessed the safety and efficacy of elafibranor in an international, randomized, double-blind placebo-controlled trial of patients with nonalcoholic steatohepatitis (NASH).METHODS: Patients with NASH without cirrhosis were randomly assigned to groups given elafibranor 80 mg (n = 93), elafibranor 120 mg (n = 91), or placebo (n = 92) each day for 52 weeks at sites in Europe and the United States. Clinical and …

0301 basic medicineLiver CirrhosisMaleTime FactorsIntention to Treat Analysi[SDV]Life Sciences [q-bio]BiopsyPLACEBO-CONTROLLED TRIALTHERAPYGastroenterologySeverity of Illness IndexChalcone0302 clinical medicineChalconesNon-alcoholic Fatty Liver DiseaseGastrointestinal AgentNonalcoholic fatty liver diseasePropionateMedicine and Health SciencesOdds RatioMedicineGlucose homeostasisVITAMIN-Eeducation.field_of_studyGastrointestinal agentFatty liverRemission InductionGastroenterologyMiddle Aged3. Good healthIntention to Treat AnalysisPPARDEuropeTreatment OutcomeLiverACIDPIOGLITAZONE030211 gastroenterology & hepatologyFemalePPARAHumanSignal TransductionAdultCLINICAL-OUTCOMESmedicine.medical_specialtyLogistic ModelTime FactorLiver CirrhosiPopulationfatty liver; NAFLD; PPARA; PPARD; Adult; Biomarkers; Biopsy; Chalcones; Double-Blind Method; Europe; Female; Gastrointestinal Agents; Humans; Intention to Treat Analysis; Liver; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Odds Ratio; PPAR alpha; PPAR gamma; Propionates; Remission Induction; Severity of Illness Index; Signal Transduction; Time Factors; Treatment Outcome; United States; GastroenterologyPlacebo03 medical and health sciencesDouble-Blind MethodGastrointestinal AgentsInternal medicineNAFLDHumansPPAR alphaeducationFATTY LIVER-DISEASEfatty liverHepatologybusiness.industryBiomarkerAMERICAN ASSOCIATIONOdds ratiomedicine.diseaseConfidence intervalUnited StatesPPAR gammaRenal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11]030104 developmental biologyEndocrinologyLogistic ModelsHuman medicinePropionatesbusinessBiomarkers
researchProduct

Standardising clinical outcomes measures for adult clinical trials in Fabry disease: A global Delphi consensus.

2021

International audience; Background: Recent years have witnessed a considerable increase in clinical trials of new investigational agents for Fabry disease (FD). Several trials investigating different agents are currently in progress; however, lack of standardisation results in challenges to interpretation and comparison. To facilitate the standardisation of investigational programs, we have developed a common framework for future clinical trials in FD.Methods and findings: A broad consensus regarding clinical outcomes and ways to measure them was obtained via the Delphi methodology. 35 FD clinical experts from 4 continents, representing 3389 FD patients, participated in 3 rounds of Delphi p…

0301 basic medicineMaleDelphi TechniqueEndocrinology Diabetes and Metabolism[SDV]Life Sciences [q-bio]Delphi methodDisease030105 genetics & heredityKidneyBiochemistry0302 clinical medicineEndocrinologyClinical outcomesClinical Trials as TopicGlobosidesTrihexosylceramidesMiddle Aged3. Good healthClinical trialIsoenzymesTreatment OutcomeInclusion and exclusion criteriaSecondary Outcome MeasureFemaleAdultmedicine.medical_specialtyConsensusLysosomal storage disorders03 medical and health sciencesQuality of life (healthcare)Inherited metabolic disordersGeneticsmedicineHumansEnzyme Replacement TherapyIntensive care medicineMolecular BiologyFabry diseaseSphingolipidsbusiness.industryClinical study designmedicine.diseaseFabry diseaseClinical trialDelphi consensusalpha-GalactosidaseQuality of LifeFabry DiseaseGlycolipidsbusiness030217 neurology & neurosurgeryMolecular genetics and metabolism
researchProduct